There remains controversy regarding the outcomes resulting from treatment versus conservative management of patent ductus arteriosus (PDA) among preterm infants. The effects of extreme prematurity, hemodynamic status of the PDA, and age at treatment remain poorly defined.
STUDY DESIGN:
This retrospective case-control study including infants < 1250 gm who were categorized into 3 groups: Group 1: without PDA, Group 2: with untreated PDA, and Group 3: treated PDA. Diagnosis and treatment of PDA extracted from the medical records. Demographics, clinical characteristics, and outcomes compared using chi-square and analysis of variance. Logistic regression used to estimate adjusted odds ratios.
RESULTS:
The study included 734 infants, with 141(19%) in Group 1, 329 (45%) in 2, and 264 (36%) in 3. Group 3 had higher incidence of bronchopulmonary dysplasia (BPD) (aOR, 2.9; 95%CI 1.7–4.8). Infant treated for hemodynamically significant PDA (HSPDA) had higher incidence of BPD (aOR, 1.9; 95%CI 1.0–3.8) and retinopathy of prematurity (ROP) (aOR, 3.4; 95%CI 1.6–6.9). There were no differences in outcome associated with treatment among≤26 weeks gestation and the age when treated.
CONCLUSION:
Infants with PDA who were treated had higher incidence of BPD. Among those who were treated, those with HSPDA had a higher incidence of BPD and ROP.
El HajjarM, VaksmannG, RakzaT, KongoloG, StormeL. Severity of the ductal shunt: A comparison of different markers. Arch Dis Chid. Fetal and Neonatal Ed. 2005;90(5), F419–F422.
2.
StollBJ, HansenNI, BellEF, ShankaranS, LaptookAR, WalshMC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatr. 2010;126(3):443–56.
3.
ShepherdJL, NooriS. What is a hemodynamically significant PDA in preterm infants?Cong Heart Dis. 2019;14:21–26.
4.
MarshallDD, KotelchuckM, YoungTE, BoseCL. Risk factors forchronic lung disease in the surfactant era: A North Carolinapopulation-based study of very low birth weight infants. NorthCarolina Neonatologists Association. Pediatr. 1999;104(6):1345–50.
5.
DollbergS, LuskyA, ReichmanB. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: A population-based study. J Pediatr Gastroenterol Nutr. 2005;40(2):184–8.
6.
EvansN, KluckowM. Early ductal shunting and intraventricular hemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996;75(3):F183–6.
7.
LeeJA. Practice for preterm patent ductus arteriosus; focusing on the hemodynamic significance and the impact on the neonatal outcomes. Korean J Pediatr. 2019;62(7):245–251.
8.
OhlssonA, ShahSS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2019;6(6):CD004213.
9.
MitraS, FlorezID, TamayoME, MbuagbawL, VanniyasingamT, VeronikiAA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: A Systematic Review and Meta-analysis. JAMA. 2018;319(12):1221–1238.
10.
SungSI, ChangYS, KimJ, ChoiJH, AhnSY, et alNatural evolution of ductus arteriosus with non-interventional conservative management in extremely preterm infants born at 23-28 weeks of gestation. PLoS One. 2019;14(2):e0212256.
11.
SlaughterJL, CuaCL, NotestineJL, RiveraBK, MarzecL, HadeEM, et al. Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation. BMC Pediatr. 2019;19(1):333.
12.
SemberovaJ, SircJ, MiletinJ, KuceraJ, BerkaI, SebkovaS, et al. Spontaneous Closure of Patent Ductus Arteriosus in Infants≤g. Pediatr. 2017;140 (2):e20164258.
13.
RollandA, Shankar-AguileraS, DiomandéD, Zupan-SimunekV, BoileauP. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed. 2015;100(1):F55–58.
14.
KochJ, HensleyG, RoyL, BrownB, RamaciottiC, RosenfeldCR. Prevalence of Spontaneous Closure of the Ductus Arteriosus in Neonates at a Birth Weight of 1000 Grams or Less. Pediatr. 2006;117 (4):1113–1121.
15.
Malekzadeh-MilaniS, AkhaviA, DouchinS, DauphinC, ChalardA, MauranP, et al. Percutaneous closure of patent ductus arteriosus in premature infants: A French national survey. Catheter Cardiovasc Interv. 2020;95(1):71–77.
16.
FicialB, CorsiniI, FiocchiS, SchenaF, CapolupoI, CerboRM, et al. On the behalf of the Italian Study Group of Neonatal Cardiology of the Italian Society of Neonatology. Survey of PDA management in very low birth weight infants across Italy. Ital J Pediatr. 2020;46(1):22–26.
17.
MitchellCC, RiveraBK, CooperJN, SmithCV, BermanDP, SlaughterJL, et al. Percutaneous closure of the patent ductus arteriosus: opportunities moving forward. Cong Heart Dis. 2019;14(1):95–99.
18.
YanH, MaF, LiY, ZhouK, HuaY, WanC. The optimal timing of surgical ligation of patent ductus arteriosus in preterm or very-low-birth-weight infants: A systematic review and meta-analysis. Med (Baltimore). 2020;99(9):e19356.
19.
ThébaudB, Lacaze-MazmonteilT. Patent ductus arteriosus in premature infants: A never-closing act. Paediatr Child Health. 2010;15(5):267–70.
ClymanRI. Patent ducus arteriosus, its treatments and the risk of pulmonary morbidity. Sem Perinatol. 2018;42:235–242.
22.
RastogiS, RajasekharH, GuptaA, BhutadaA, RastogiD, WungJT. Factors Affecting theWeaning from Nasal CPAP in Preterm Neonates. Int J Pediatr. 2012:416073.
23.
Borràs-NovellC, RiverolaA, Aldecoa-BilbaoV, IzquierdoM, DomingoM. Clinical outcomes after more conservative management of patent ductus arteriosus in preterm infants. J Pediatr (Rio J). 2020;96(2):177–183.
24.
PavageauL, BrionLP, RosenfeldCR, BrownLS, RamaciottiC, BurchfieldPJ, et al. Decrease in the frequency of treatment for patent ductus arteriosus after implementation of consensus guidelines: a 15-year experience. J Perinatol. 2019;39(11):1569–1576.
25.
SungSI, ChangYS, ChunJY, YoonSA, YooHS, AhnSY, et al. Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants. J Pediatr. 2016;177:66–71.e1.
26.
SchenaF, FrancescatoG, CappelleriA, PicciolliI, MayerA, MoscaF, et al. Association between Hemodynamically Significant Patent Ductus Arteriosus and Bronchopulmonary Dysplasia. J Pediatr. 2015;166(6):1488–92.
27.
LiebowitzM, ClymanRI. Prophylactic indomethacin compared with delayed conservative management of the patent ductus arteriosus in extremely preterm infants: Effects on neonatal outcomes. J Pediatr. 2017;187:119–126.e1.
PaudelG, JoshiV. Echocardiography of the patent ductus arteriosus in premature infant. Cong Heart Dis. 2019;14(1):42–45.
30.
Van der LaanME, RoofthooftMT, FriesMW, BergerRM, SchatTE, van ZoonenAG, et alA Hemodynamically Significant Patent Ductus Arteriosus Does Not Affect Cerebral or Renal Tissue Oxygenation in Preterm Infants. Neonatol. 2016;110(2):141–7.
31.
GudmundsdottirA, JohanssonS, HåkanssonS, NormanM, KällenK, BonamyAK. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. Neonatol. 2015;107(2):87–92.
32.
SosenkoIR, FajardoMF, ClaureN, BancalariE. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: A double-blind randomized controlled trial. J Pediatr. 2012;160(6):929–35.e1.
33.
ElhoffJJ, EbelingM, HulseyTC, AtzAM. Potential unintended consequences of a conservative management strategy for patent ductus arteriosus. Cong Heart Dis. 2016;11(1):52–57.
34.
Khanafer-LarocqueI, SoraishamA, StritzkeA, Al AwadE, ThomasS, MurthyP, et al. Intraventricular Hemorrhage: Risk factors and association with patent ductus arteriosus treatment in extremely preterm neonates. Front Pediatr. 2019;7:408–414.
